Baloxavir (Xofluza) Dosing and Clinical Use Guidelines

Indications and Timing of Therapy

Weight‑Based Dosing

Adults and Adolescents (≥ 12 years)

Pediatric Patients (5–11 years) – Formulation Availability

Administration Considerations

Contraindications and Special Populations

Clinical Efficacy

Pediatric Efficacy and Safety Signals

Practical Implementation Algorithm

All statements are supported by the cited references.

Baloxavir (Xofluza) Dosing and Clinical Guidance for Pediatric Influenza Patients

Dosing Recommendations

• For children weighing 20 kg – < 40 kg, a single oral dose of 40 mg is recommended. (Pediatric dosing guideline) 6
• For adolescents and adults weighing 40 kg – < 80 kg, a single oral dose of 40 mg is recommended. (Pediatric dosing guideline) 7
• For patients weighing ≥ 80 kg, a single oral dose of 80 mg is recommended. (Pediatric dosing guideline) 7

Formulation Availability

• The oral suspension needed for children < 20 kg was not available in the United States during the 2023‑2024 influenza season, and its availability for 2024‑2025 is uncertain, limiting use in this weight group. (Formulation supply report) 8, 9

Administration Timing

• Treatment should be initiated within 48 hours of symptom onset to achieve optimal antiviral efficacy. (Therapeutic window evidence) 8

Contraindications

• Children younger than 12 months are not FDA‑approved for baloxavir therapy. (Regulatory guidance) 6

Comparative Efficacy

• In pediatric patients, baloxavir shows similar time to symptom alleviation compared with oseltamivir. (Head‑to‑head trial) 8
• In randomized controlled trials, baloxavir demonstrated superior efficacy against influenza B infections relative to oseltamivir. (RCT evidence) 8, 9
• Baloxavir achieved a more rapid reduction in viral load than oseltamivir. (Virologic outcome study) 8, 9

Safety Signals in Young Children

• Post‑hoc analyses of Japanese studies in children < 6 years reported symptom recurrence after day 4 in 54.5 % and fever recurrence in 50 % of treated patients, indicating the need for close monitoring despite overall tolerability. (Safety surveillance) 8, 9

Practical Pitfalls

• Do not prescribe baloxavir for children < 20 kg when the oral suspension is unavailable; only tablet formulations are accessible in most U.S. settings. (Prescribing caution) 8, 9
• Do not delay therapy beyond 48 hours from symptom onset, as efficacy declines sharply after this window. (Timing recommendation) 8

Decision‑Making Guidance

• Consider baloxavir instead of oseltamivir when:
  
  • Adherence to a 5‑day, twice‑daily regimen is a concern. (Compliance advantage) 8
  • Patients have poor tolerance of multiple‑dose antiviral regimens. (Tolerance consideration) 8
  • Influenza B infection is confirmed or strongly suspected. (Pathogen‑specific benefit) 8, 9
  • Patient or family prefers a single‑dose therapy. (Preference factor) 8
• Oseltamivir remains the first‑line antiviral for most pediatric patients, especially those under 5 years, due to a broader evidence base and the lack of formulation barriers. (First‑line recommendation) 8, 10